|
Foghorn Therapeutics Inc. (FHTX) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Foghorn Therapeutics Inc. (FHTX) Bundle
Simplifiez l'évaluation Foghorn Therapeutics Inc. (FHTX) avec cette calculatrice DCF personnalisable! Doté de Real Foghorn Therapeutics Inc. (FHTX) Financials and Rajustement des entrées de prévision, vous pouvez tester les scénarios et découvrir la juste valeur Foghorn Therapeutics Inc. (FHTX) en minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .4 | 1.3 | 19.2 | 34.2 | 57.9 | 98.0 | 166.1 | 281.3 | 476.6 |
| Revenue Growth, % | 0 | 0 | 206.74 | 1357.77 | 77.63 | 69.41 | 69.41 | 69.41 | 69.41 | 69.41 |
| EBITDA | -48.8 | -66.5 | -96.2 | -113.8 | -104.5 | -34.7 | -58.8 | -99.6 | -168.8 | -285.9 |
| EBITDA, % | 100 | -15463.72 | -7292.42 | -591.93 | -305.83 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 1.8 | 5.5 | 7.5 | 7.9 | 3.5 | 40.6 | 68.8 | 116.6 | 197.6 | 334.7 |
| Depreciation, % | 100 | 1285.58 | 569.75 | 41.09 | 10.1 | 70.24 | 70.24 | 70.24 | 70.24 | 70.24 |
| EBIT | -50.6 | -72.0 | -103.7 | -121.7 | -107.9 | -34.7 | -58.8 | -99.6 | -168.8 | -285.9 |
| EBIT, % | 100 | -16749.3 | -7862.17 | -633.02 | -315.93 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 15.0 | 185.8 | 154.3 | 345.8 | 234.1 | 57.9 | 98.0 | 166.1 | 281.3 | 476.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 300.0 | .0 | .0 | 23.1 | 39.2 | 66.4 | 112.5 | 190.6 |
| Account Receivables, % | 100 | 0 | 22744.5 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 11.6 | 19.6 | 33.2 | 56.3 | 95.3 |
| Inventories, % | 100 | 0 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | 3.4 | 3.7 | 3.8 | 5.4 | 6.3 | 40.1 | 67.9 | 115.1 | 194.9 | 330.2 |
| Accounts Payable, % | 100 | 855.81 | 289.54 | 28.16 | 18.33 | 69.3 | 69.3 | 69.3 | 69.3 | 69.3 |
| Capital Expenditure | -1.0 | -16.2 | -3.3 | -1.2 | -1.2 | -24.3 | -41.1 | -69.7 | -118.1 | -200.0 |
| Capital Expenditure, % | 100 | -3763.49 | -251.18 | -6.29 | -3.58 | -41.98 | -41.98 | -41.98 | -41.98 | -41.98 |
| Tax Rate, % | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 |
| EBITAT | -51.1 | -73.0 | -105.7 | -121.7 | -112.7 | -34.7 | -58.8 | -99.6 | -168.8 | -285.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -46.9 | -83.5 | -401.3 | 186.6 | -109.7 | -19.2 | -27.4 | -46.4 | -78.6 | -133.1 |
| WACC, % | 16.35 | 16.35 | 16.35 | 16.35 | 16.35 | 16.35 | 16.35 | 16.35 | 16.35 | 16.35 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -171.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -136 | |||||||||
| Terminal Value | -946 | |||||||||
| Present Terminal Value | -444 | |||||||||
| Enterprise Value | -615 | |||||||||
| Net Debt | -35 | |||||||||
| Equity Value | -580 | |||||||||
| Diluted Shares Outstanding, MM | 42 | |||||||||
| Equity Value Per Share | -13.82 |
What You Will Get
- Pre-Filled Financial Model: Foghorn Therapeutics Inc.'s (FHTX) actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers specific to FHTX.
- Instant Calculations: Automatic updates ensure you see results as you make changes to FHTX's financials.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation of FHTX.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts of FHTX.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as drug development timelines, market penetration rates, and R&D expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, net present value (NPV), and other financial metrics.
- High-Precision Accuracy: Leverages Foghorn Therapeutics' actual financial data for credible valuation insights.
- Streamlined Scenario Testing: Easily evaluate various hypotheses and analyze different outcomes.
- Efficiency Booster: Avoid the complexities of creating detailed valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Foghorn Therapeutics Inc.'s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Foghorn Therapeutics Inc. (FHTX)?
- Precision: Utilizes accurate Foghorn Therapeutics financial data for reliable calculations.
- Customizability: Allows users to adjust and experiment with various inputs seamlessly.
- Efficiency: Eliminates the need to create a financial model from the ground up.
- Expert-Level: Crafted with the expertise and detail expected at the CFO level.
- Intuitive: Designed for ease of use, catering to individuals with varying levels of financial expertise.
Who Should Use This Product?
- Investors: Evaluate Foghorn Therapeutics Inc.'s (FHTX) valuation before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and assess future projections for FHTX.
- Biotech Entrepreneurs: Understand the valuation models applied to companies like Foghorn Therapeutics Inc. (FHTX).
- Consultants: Create comprehensive valuation reports for clients in the biotech sector.
- Students and Educators: Utilize current market data to explore and teach valuation strategies in biotechnology.
What the Template Contains
- Pre-Filled Data: Includes Foghorn Therapeutics Inc.'s (FHTX) historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Foghorn Therapeutics Inc.'s (FHTX) profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.